Deutsche Bank AG Analysts Give MorphoSys AG (MOR) a €90.00 Price Target

Deutsche Bank AG set a €90.00 ($105.88) price target on MorphoSys AG (ETR:MOR) in a research report report published on Monday, August 7th. The firm currently has a buy rating on the stock.

Several other equities research analysts have also recently issued reports on MOR. Berenberg Bank set a €68.00 ($80.00) price objective on shares of MorphoSys AG and gave the stock a buy rating in a research report on Thursday, May 25th. Independent Research GmbH set a €77.00 ($90.59) price objective on shares of MorphoSys AG and gave the stock a buy rating in a research report on Monday, May 29th. Commerzbank Ag set a €76.00 ($89.41) price objective on shares of MorphoSys AG and gave the stock a buy rating in a research report on Tuesday, May 30th. Goldman Sachs Group, Inc. (The) set a €55.00 ($64.71) price objective on shares of MorphoSys AG and gave the stock a neutral rating in a research report on Tuesday, June 6th. Finally, HSBC Holdings plc set a €59.00 ($69.41) price objective on shares of MorphoSys AG and gave the stock a neutral rating in a research report on Friday, July 14th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of Buy and an average price target of €69.57 ($81.85).

MorphoSys AG (ETR MOR) opened at 56.922 on Monday. The company’s 50 day moving average is €61.24 and its 200-day moving average is €57.85. MorphoSys AG has a 1-year low of €35.72 and a 1-year high of €70.90. The stock’s market cap is €1.65 billion.

WARNING: “Deutsche Bank AG Analysts Give MorphoSys AG (MOR) a €90.00 Price Target” was published by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at https://www.com-unik.info/2017/08/19/morphosys-ag-mor-pt-set-at-90-00-by-deutsche-bank-ag-updated.html.

MorphoSys AG Company Profile

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.

Analyst Recommendations for MorphoSys AG (ETR:MOR)

What are top analysts saying about MorphoSys AG? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for MorphoSys AG and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit